DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Read More…
Industry, Sector and Symbol
Industry Dental equipment & supplies
Sub-IndustryHealth Care Supplies
SectorMedical
Phone844-546-3722
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.99 billion
Profitability
Miscellaneous
Employees16,400
Next Earnings Date3/2/2020 (Confirmed)
OptionableOptionable
DENTSPLY SIRONA (NASDAQ:XRAY) Frequently Asked Questions
What is DENTSPLY SIRONA's stock symbol?
DENTSPLY SIRONA trades on the NASDAQ under the ticker symbol "XRAY."
How often does DENTSPLY SIRONA pay dividends? What is the dividend yield for DENTSPLY SIRONA?
DENTSPLY SIRONA announced a quarterly dividend on Friday, December 13th. Investors of record on Friday, December 27th will be paid a dividend of $0.10 per share on Friday, January 10th. This represents a $0.40 annualized dividend and a yield of 0.70%. The ex-dividend date of this dividend is Thursday, December 26th. View DENTSPLY SIRONA's Dividend History.
How were DENTSPLY SIRONA's earnings last quarter?
DENTSPLY SIRONA Inc (NASDAQ:XRAY) released its quarterly earnings results on Thursday, November, 7th. The medical instruments supplier reported $0.57 EPS for the quarter, beating the Zacks' consensus estimate of $0.50 by $0.07. The medical instruments supplier earned $962.10 million during the quarter, compared to analysts' expectations of $940.38 million. DENTSPLY SIRONA had a net margin of 4.08% and a return on equity of 10.08%. The business's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.38 EPS. View DENTSPLY SIRONA's Earnings History.
When is DENTSPLY SIRONA's next earnings date?
How can I listen to DENTSPLY SIRONA's earnings call?
DENTSPLY SIRONA will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for XRAY?
10 brokerages have issued 1-year target prices for DENTSPLY SIRONA's stock. Their forecasts range from $50.00 to $65.00. On average, they expect DENTSPLY SIRONA's share price to reach $58.08 in the next year. This suggests a possible upside of 1.3% from the stock's current price. View Analyst Price Targets for DENTSPLY SIRONA.
What is the consensus analysts' recommendation for DENTSPLY SIRONA?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DENTSPLY SIRONA in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for DENTSPLY SIRONA.
What are Wall Street analysts saying about DENTSPLY SIRONA stock?
Here are some recent quotes from research analysts about DENTSPLY SIRONA stock:
- 1. According to Zacks Investment Research, "DENTSPLY ended the third quarter on a solid note. Significant increase in the bottom line bodes well. The company gained from its core Technology & Equipment unit that witnessed year-over-year upside in the quarter. Overall sales grew on an internal basis. Internationally, revenues surged as well. The company raised earnings per share guidance, which indicates bright prospects. Product launches are encouraging. Significant expansion in margins is another positive. The stock has outperformed the industry in a year. Meanwhile, sales of Restorative and Endodontics products as well as Laboratory Dental products witnessed some softness in the quarter. Additionally, unfavorable foreign currency exchange and restructuring costs are expected to exert pressure on DENTSPLY SIRONA’s top line in 2019. The stock is overvalued at the moment." (12/10/2019)
- 2. Barrington Research analysts commented, "We are now modeling $2.35, up from our prior $2.32 estimate." (8/5/2019)
Has DENTSPLY SIRONA been receiving favorable news coverage?
News headlines about XRAY stock have been trending neutral on Tuesday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DENTSPLY SIRONA earned a news sentiment score of 0.3 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the immediate future. View News Stories for DENTSPLY SIRONA.
Are investors shorting DENTSPLY SIRONA?
DENTSPLY SIRONA saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 3,080,000 shares, a decrease of 13.0% from the January 15th total of 3,540,000 shares. Based on an average daily volume of 1,343,500 shares, the short-interest ratio is presently 2.3 days. Approximately 1.4% of the shares of the stock are short sold. View DENTSPLY SIRONA's Current Options Chain.
Who are some of DENTSPLY SIRONA's key competitors?
Some companies that are related to DENTSPLY SIRONA include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), Antares Pharma (ATRS), Anika Therapeutics (ANIK), OraSure Technologies (OSUR) and Utah Medical Products (UTMD).
What other stocks do shareholders of DENTSPLY SIRONA own?
Who are DENTSPLY SIRONA's key executives?
DENTSPLY SIRONA's management team includes the folowing people:
- Mr. Nicholas William Alexos, Exec. VP & CFO (Age 55)
- Mr. Keith John Ebling, EVP, Gen. Counsel & Sec. (Age 50)
- Ms. Maureen J. MacInnis, Sr. VP, Chief HR Officer & Communications (Age 58)
- Mr. Donald M. Casey Jr., CEO & Director (Age 59)
- Mr. Dominique P. Legros, Sr. VP of Equipment, Technologies & Healthcare Segment (Age 59)
Who are DENTSPLY SIRONA's major shareholders?
DENTSPLY SIRONA's stock is owned by a number of of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (5.04%), State Street Corp (4.37%), First Eagle Investment Management LLC (2.81%), Janus Henderson Group PLC (2.64%), Goldman Sachs Group Inc. (1.82%) and Champlain Investment Partners LLC (1.63%). Company insiders that own DENTSPLY SIRONA stock include Betsy D Holden, Daniel P Key, Donald M Jr Casey, Eric Brandt, Gregory T Lucier, Markus Boehringer, Maureen J Macinnis, Michael C Alfano, Michael J Coleman, Nicholas W Alexos and William E Newell. View Institutional Ownership Trends for DENTSPLY SIRONA.
Which major investors are selling DENTSPLY SIRONA stock?
XRAY stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, AQR Capital Management LLC, FMR LLC, Nuance Investments LLC, Douglas Lane & Associates LLC, Man Group plc, Massachusetts Financial Services Co. MA and SG Americas Securities LLC. Company insiders that have sold DENTSPLY SIRONA company stock in the last year include Eric Brandt, Markus Boehringer, Maureen J Macinnis, Michael C Alfano, Michael J Coleman and William E Newell. View Insider Buying and Selling for DENTSPLY SIRONA.
Which major investors are buying DENTSPLY SIRONA stock?
XRAY stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Goldman Sachs Group Inc., Prudential Financial Inc., Parnassus Investments CA, Anchor Capital Advisors LLC, Bank of America Corp DE, Champlain Investment Partners LLC and Pragma Gestao DE Patrimonio Ltd.. Company insiders that have bought DENTSPLY SIRONA stock in the last two years include Betsy D Holden, Daniel P Key, Donald M Jr Casey, Gregory T Lucier and Nicholas W Alexos. View Insider Buying and Selling for DENTSPLY SIRONA.
How do I buy shares of DENTSPLY SIRONA?
Shares of XRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is DENTSPLY SIRONA's stock price today?
One share of XRAY stock can currently be purchased for approximately $57.33.
How big of a company is DENTSPLY SIRONA?
DENTSPLY SIRONA has a market capitalization of $12.75 billion and generates $3.99 billion in revenue each year. The medical instruments supplier earns $-1,011,000,000.00 in net income (profit) each year or $2.01 on an earnings per share basis. DENTSPLY SIRONA employs 16,400 workers across the globe.View Additional Information About DENTSPLY SIRONA.
What is DENTSPLY SIRONA's official website?
How can I contact DENTSPLY SIRONA?
DENTSPLY SIRONA's mailing address is 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC, 28277. The medical instruments supplier can be reached via phone at 844-546-3722 or via email at [email protected]
MarketBeat Community Rating for DENTSPLY SIRONA (NASDAQ XRAY)
MarketBeat's community ratings are surveys of what our community members think about DENTSPLY SIRONA and other stocks. Vote "Outperform" if you believe XRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
